dc.contributor.author | Efe, C | |
dc.contributor.author | Lammert, C | |
dc.contributor.author | Tascilar, K | |
dc.contributor.author | Dhanasekaran, R | |
dc.contributor.author | Ebik, B | |
dc.contributor.author | Higuera-de la Tijera, F | |
dc.contributor.author | Caliskan, AR | |
dc.contributor.author | Peralta, M | |
dc.contributor.author | Gerussi, A | |
dc.contributor.author | Massoumi, H | |
dc.contributor.author | Catana, AM | |
dc.contributor.author | Purnak, T | |
dc.contributor.author | Rigamonti, C | |
dc.contributor.author | Aldana, AJG | |
dc.contributor.author | Khakoo, N | |
dc.contributor.author | Nazal, L | |
dc.contributor.author | Frager, S | |
dc.contributor.author | Demir, N | |
dc.contributor.author | Irak, K | |
dc.contributor.author | Melekoglu-Ellik, Z | |
dc.contributor.author | Kacmaz, H | |
dc.contributor.author | Balaban, Y | |
dc.contributor.author | Atay, K | |
dc.contributor.author | Eren, F | |
dc.contributor.author | Alvares-da-Silva, MR | |
dc.contributor.author | Cristoferi, L | |
dc.contributor.author | Urzua, A | |
dc.contributor.author | Eskazan, T | |
dc.contributor.author | Magro, B | |
dc.contributor.author | Snijders, R | |
dc.contributor.author | Barutcu, S | |
dc.contributor.author | Lytvyak, E | |
dc.contributor.author | Zazueta, GM | |
dc.contributor.author | Demirezer-Bolat, A | |
dc.contributor.author | Aydin, M | |
dc.contributor.author | Heurgue-Berlot, A | |
dc.contributor.author | De Martin, E | |
dc.contributor.author | Ekin, N | |
dc.contributor.author | Yildirim, S | |
dc.contributor.author | Yavuz, A | |
dc.contributor.author | Biyik, M | |
dc.contributor.author | Narro, GC | |
dc.contributor.author | Kiyici, M | |
dc.contributor.author | Akyildiz, M | |
dc.contributor.author | Kahramanoglu-Aksoy, E | |
dc.contributor.author | Vincent, M | |
dc.contributor.author | Carr, RM | |
dc.contributor.author | Gunsar, F | |
dc.contributor.author | Reyes, EC | |
dc.contributor.author | Harputluoglu, M | |
dc.contributor.author | Aloman, C | |
dc.contributor.author | Gatselis, NK | |
dc.contributor.author | Ustundag, Y | |
dc.contributor.author | Brahm, J | |
dc.contributor.author | Vargas, NCE | |
dc.contributor.author | Guzelbulut, F | |
dc.contributor.author | Garcia, SR | |
dc.contributor.author | Aguirre, J | |
dc.contributor.author | Anders, M | |
dc.contributor.author | Ratusnu, N | |
dc.contributor.author | Hatemi, I | |
dc.contributor.author | Mendizabal, M | |
dc.contributor.author | Floreani, A | |
dc.contributor.author | Fagiuoli, S | |
dc.contributor.author | Silva, M | |
dc.contributor.author | Idilman, R | |
dc.contributor.author | Satapathy, SK | |
dc.contributor.author | Silveira, M | |
dc.contributor.author | Drenth, JPH | |
dc.contributor.author | Dalekos, GN | |
dc.contributor.author | Assis, DN | |
dc.contributor.author | Bjornsson, E | |
dc.contributor.author | Boyer, JL | |
dc.contributor.author | Yoshida, EM | |
dc.contributor.author | Invernizzi, P | |
dc.contributor.author | Levy, C | |
dc.contributor.author | Montano-Loza, AJ | |
dc.contributor.author | Schiano, TD | |
dc.contributor.author | Ridruejo, E | |
dc.contributor.author | Wahlin, S | |
dc.date.accessioned | 2022-10-11T12:58:51Z | |
dc.date.available | 2022-10-11T12:58:51Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | http://hdl.handle.net/11616/74873 | |
dc.description.abstract | Background We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH. | |
dc.source | LIVER INTERNATIONAL | |
dc.title | Effects of immunosuppressive drugs on COVID-19 severity in patients with | |
dc.title | autoimmune hepatitis |
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |